Dendritic cell (DC)-based immunotherapy has been hampered by the lack of suitable methods for antigen delivery. Here, we use biodegradable poly(d,l-lactide-co-glycolide) microspheres (PLGA-MS) as carriers of peptides and proteins for antigen delivery to human monocyte-derived DC (MoDC). Compared to soluble proteins, MHC classes I and II-restricted presentation of PLGA-MS-encapsulated proteins and peptides by MoDC was markedly prolonged and proteins were presented 50-fold more efficiently on class I molecules. The vaccination of mice with DC loaded with PLGA-MS-encapsulated proteins raised strong and persisting cytotoxic T cell responses. In conclusion, antigen delivery via PLGA-MS markedly enhanced the duration of antigen presentation by human MoDC and the potency of DC-based vaccination.
Introduction
Dendritic cells (DC) are antigen presenting cells that function as master switches in the regulation of T cell mediated immune responses [1] . The combination of several properties make them unique which implies that other cell types can not substitute for their function in the priming of T cells in vivo [2] . One of these properties is a great capacity for the uptake of soluble and particulate material [3] . A second property is the ability to sense pathogens via toll-like receptors. The contact with prototypic pathogen-derived molecules triggers a third property, i.e. the ability to differentiate from an immature to a mature state. Maturation changes their migratory behaviour such that they migrate from a peripheral site of infection into the T cell zones of the draining lymph nodes. A further special trait of DC is their ability to process endocytotically acquired material in a way that peptides become cross-presented on MHC class I molecules. The intracellular pathways of cross-presentation in DC are still a matter of investigation [4] , but it is remarkable that microparticulate materials are cross-presented by DC much more efficiently than soluble antigens [5] .
Due to these features and their potency in T cell stimulation, DC have been investigated as cellular vaccines in immunotherapy against tumors and infectious diseases. Inoculation of antigen-loaded DC is one of the most powerful ways to trigger a T cell response, and numerous phase I/II clinical trials have been published that were based on vaccination with antigen-loaded autologous DC [6] . Protocols to generate large numbers of immature DC from peripheral blood monocytes by differentiation in IL-4 and GM-CSF [7] as well as procedures to reliably mature and cryopreserve monocyte derived DC (MoDC) [8] have greatly facilitated this approach. While it emerged that DC-based vaccination is feasible and well tolerated, it became evident that the CTL responses in patients were not overwhelming, and clinical responses were confined to a small subset of patients.
One likely reason, why DC-based tumor immunotherapy in humans has remained inefficient, is a lack of suitable methods for antigen delivery to MoDC. Most trials published to date relied on externally pulsing MoDC with synthetic class I peptides. Because of the rapid turn over of class Ipeptide complexes on the cell surface, the duration of T cell stimulation in vivo is probably not long enough. In mice, it has been shown that the ability of peptide-pulsed DC to stimulate antigen-specific CTL was lost within a day after injection, whereas DC that endogenously expressed the same antigen could activate antigen specific CTLs for more than 2 days [9] . The external loading with class I epitopes is also unsatisfactory, because it confines immunotherapy to patients expressing a certain restriction element and because antigenspecific help is not provided. It would be optimal to charge MoDC with entire protein antigens, that are likely to contain several MHC classes I and II-restricted epitopes, and deliver the proteins in a form such that they can be taken up efficiently by DC and provide T cell epitopes over an extended time period.
In order to achieve these aims, we have investigated biodegradable poly(d,l-lactide-co-glycolide) microspheres (PLGA-MS) as carriers of peptides and proteins for antigen delivery to human MoDC. PLGA-MS are microparticles that are slowly hydrolyzed in an aqueous environment and have been used as drug delivery vehicles for sustained release in humans [10] . PLGA-MS have previously been investigated as single dose vaccine formulations which elicited potent antibody [11] [12] [13] as well as Th and CTL responses [14] [15] [16] [17] against encapsulated peptides or proteins. The PLGA polymer used in this study is composed of 50% glycolate and 50% lactate and is hydrolyzed in aqueous media over a period of approximately 20-30 days during which encapsulated peptides and proteins are released [18] . By spray-drying, peptides, proteins or DNA can be microencapsulated into PLGA-MS of a size range of 0.5-5 m. Particles of such sizes can be efficiently phagocytosed by murine macrophages and DC in vitro and in vivo [19, 20] , and antigen presentation of T cell epitopes on MHC classes I and II molecules has been demonstrated [5, 21, 22] .
Previously, we have shown that MoDC, which were generated in serum-free medium according to a protocol suited for clinical application [23] , readily take up PLGA-MS without adverse effects on their phenotype, cytokine production, allostimulatory potential, survival, and migration [20] . In this study, we investigated MHC class Irestricted cross-presentation and MHC class II-restricted direct presentation of peptides and proteins that were taken up by human MoDC in a PLGA-MS encapsulated form. We show that this technique of antigen delivery allows efficient and long-lasting antigen presentation by MoDC in vitro and the generation of strong CTL responses in vivo.
Materials and methods

Materials and cell culture reagents
PLGA 50:50 of approx. 14 kDa and carrying uncapped hydroxyl and carboxyl end-groups (Resomer ® RG502H) was purchased from Boehringer Ingelheim (Ingelheim, Germany), AIM-V medium from Invitrogen (Groningen, The Netherlands), MDM medium and FCS from Sigma (Buchs, Switzerland) and Ficoll-Paque ® from Pharmacia (Uppsala, Sweden). Human GM-CSF (Leukine ® ) was obtained from Immunex (Seattle, WA, USA), Human recombinant cytokines IL-4, TNF-␣, IL-1␤, and IL-6 were bought from CellGenix (Freiburg, Germany). Murine GM-CSF was kindly provided by Novartis (Vienna, Austria). LPS (from Salmonella abortus equi) and ␤-galactosidase (␤-Gal) were bought from Sigma. PGE2 was obtained from Pharmacia & Upjohn (Dübendorf, Switzerland) and Tetanus toxoid from Berna Biotech (Berne, Switzerland). HLA-A * 0201-restricted peptide FluM 58-66 (Influenza A M1 protein 58-66, amino acid sequence GILGFVFTL), HLA-DR5-restricted peptide tt30 (tetanus toxrn 947-967 , FNNFTVSFWLRVPKVSASHLE) and H-2K b -restricted peptide I8V (␤-Gal 497-504, ICPMYARV) were synthesized by Echaz Microcollections (Reutlingen, Germany). PE-labeled I8V/H-2K b tetramer was a gift from Philippe Krebs (Institute of Experimental Immunology, University Hospital Zurich, Switzerland).
Preparation of GST-FluM fusion protein
A glutathion-S-transferase-influenza virus matrix (GSTFluM) expression construct was kindly provided by Dr.
Stephan Ludwig, University of Würzburg. BL21 cells were transfected with the GST-FluM expression plasmid and grown at 28 • C. GST-FluM expression was induced with 0.5 mM isopropyl ␤-d-1-thiogalactopyranoside (IPTG) for 6 h and cells were pelleted and lysed by ultrasound treatment and extracted with 1% Triton X-100. The insoluble debris was removed by centrifugation and GST-FluM protein was purified over a glutathion-sepharose matrix (Amersham Biosiences, Freiburg, Germany) according to standard protocols.
Microencapsulation of antigens
All antigens used in this study were microencapsulated into PLGA 50:50 of a size of 0.5-5 m by spray-drying as previously described [20] . Briefly, 10 or 20 mg of antigen were dissolved in 1 ml of phosphate buffered saline and 1 g of PLGA in 20 ml ethyl formate. The two solutions were mixed and homogenized under ultrasonication (20 kHz, 50 W, VibraCell VC50T, Sonics & Materials, Danbury, CT) during 2 × 30 s under cooling on ice. This w/o-dispersion was spray-dried (Mini Spray-Dryer 191, Büchi, CH-Flawil) at a flow rate of 2 ml/min, and at inlet and outlet temperatures of 48 and 40 • C, respectively. The spray-dried MS were washed out of the spray-dryer's cyclone and product recipient with 0.1% poloxamer 188 solution, collected on a cellulose acetate membrane filter, washed with water to remove non-encapsulated protein, and dried under reduced pressure (20 mbar) for 24 h. The antigen contents of the resulting MS were as follows: MS-tt30, 6.7 g/mg; MS-TT, 12 g/mg; MS-Flu peptide, 5.7 g/mg; MS-FluM, 4.2 g/mg; MS-I8V, 6 g/mg; MS-PGal, 4.7 g/mg.
Generation of DC and antigen loading with PLGA-MS
Human MoDC were generated from peripheral blood mononuclear cells (PBMC) under clinical conditions as previously described [20] . After 5 days of differentiation in IL-4 and GM-CSF, cells were collected for flow cytometric analysis as described elsewhere [20] . The cells showed a typical phenotype of immature DC (CD1a + , CD3 − , CD11c + , CD14 − , CD16 − , CD20 − , CD40 + , CD80 + , CD83 − , CD86 + , CD95 + , MNR + , MHC classes I and II molecules positive, and CCR7 − ), and were hence designated immature MoDC. Where indicated, a cocktail containing 20 ng/ml TNF-␣, 10 ng/ml IL-1␤, 1000 U/ml IL-6, and 1 g/ml PGE2 was added to immature MoDC previously loaded or not with soluble or encapsulated antigens. Upregulation of CD40, CD80, CD83, CD86, MHC class II molecules and CCR7, and downregulation of MNR was observed after 2 days of maturation; the cells were hence called mature MoDC (Fig. 1) .
Murine BM-DC were generated as previously described [20] . Where indicated, 1 g/ml LPS was added to Ag-loaded BM-DC for 24 h for further DC activation.
To deliver MS-encapsulated antigens to human MoDC or mouse BM-DC, the indicated amounts of PLGA-MS were first dispersed in cell culture medium by ultrasonication for 1 min in order to disintegrate microparticulate aggregates and obtain a very homogenous suspension of primary microsphere particles. Then these microsphere suspensions were added to immature MoDC or BM-DC cultures. After 4 h of incubation at 37 • C, about 50-60% of DC had ingested at least one PLGA particle (data not shown). Where indicated, proinflammatory cytokines (for MoDC) or LPS (for BM-DC) were added to activate DC for another 2 days before analysis of antigen presentation.
Generation of T cell lines
Human CD4 + T cell lines SK.30 (specific to tt30 peptide) and KR.TT (specific to tetanus toxoid protein (TT)) were generated in our laboratory. Briefly, CD4 + cells from a HLA-DR5 + donor were magnetically isolated by CD4 + MACS microbeads and resuspended in T cell medium (IMDM medium supplemented with 10% AB serum, 1% HEPES, 100 U/ml penicillin, and 100 g/ml streptomycin) at 2 × 10 6 /ml and cultured in 24-well plates. These cells were weekly restimulated with irradiated (30 Gy) autologous PBMC pulsed with either 10 g/ml tt30 or TT. After 4-6 , or first loaded with the antigens for 4 h at 37 • C and then proinflammatory cytokines were added for maturation for 2 days (mMoDC, C/D). MoDC were co-cultured with tt30-specific CD4 + T cells SK.30 and proliferation was measured by 3 H-thymidine incorporation ( Fig. 2A-D) . (E/F) MoDC were loaded with soluble TT or MS-TT with (F) or without maturation (E) as described above. MoDC were then co-cultured with the TT specific CD4 + T cell line KR.TT and T cell proliferation was determined. (G/H) MoDC were loaded with a high (1 g/ml, G) or low dose (0.01 g/ml, H) of TT in soluble or in PLGA-MS-encapsulated form and matured. KR.TT cells were added to TT-loaded MoDC on day 2, 6 or 10, respectively, to evaluate the kinetics of TT presentation by MoDC. All data are shown as the mean cpm from duplicate cultures ± S.E.M. and summarized from four independent experiments. Empty PLGA-MS (MS-E) or untreated MoDC (MoDC alone) served as negative controls as indicated.
restimulations, cells were tested for T cell proliferation with MoDC pulsed with relevant antigens (data not shown).
Human CD8 + CTL line Flu.2 specific to Flu 58-66 peptide was generated from PBMC of an HLA-A * 0201 + donor who had received Flu vaccination recently. In brief, CD8 + cells were magnetically isolated from PBMC, suspended in T cell medium at 2 × 10 6 /ml, and cultured in 24-well plates. Autologous matured MoDC were pulsed with 5 g/ml Flu peptide for 2 h at 37 • C, irradiated (30 Gy) and added to CD8 + cell culture at 5 × 10 5 /well. Autologous PBMC were irradiated (35 Gy) and used as feeder cells (4 × 10 6 /well). After six restimulations, CD8 + CTL were tested for their antigen specificity with Flu/HLA-A2-tetramer staining and for cytotoxicity with 51 Cr release assay. A portion of >50% of CTL were Flu/HLA-A2-tetramer positive and demonstrated a high level of Flu-peptide-specific cytotoxicity (data not shown).
Determination of antigen presentation by human MoDC in vitro
To present MHC class II antigens to CD4 + T cells, MoDC were loaded with soluble or PLGA-MS-encapsulated tt30 or TT at various concentrations as indicated in Fig. 2 . Subsequently, MoDC were resuspended in T cell medium and seeded into 96-well flat bottom microplates at 5 × 10 4 MoDC in 100 l per well. SK.30 ( Fig. 2A-D) or KR.TT ( Fig. 2E-H ) T cells were added to the MoDC culture at 1 × 10 5 per well (100 l) for co-incubation in duplicates at the indicated time points. After 3 days of co-culture, 3 H-thymidine (1 Ci/well) was added for 16-18 h, and T cell proliferation was determined by 3 H-thymidine incorporation.
To study the presentation of Flu antigens to CD8 + CTL by MoDC (Fig. 3) , soluble or PLGA-MS-encapsulated Flu peptide or GST-FluM protein were co-incubated with immature MoDC, and subsequently, maturation stimuli were provided as described above. Antigen-loaded matured MoDC were collected, washed and resuspended in T cell medium and seeded into 96-well U-bottom microplates. Flu.2 CTL were added to the antigen-loaded MoDC culture at the indicated time points. After 24 h of co-culture, supernatants were collected and analyzed for IFN-␥ content with a human IFN-␥ ELISA kit (BD OptEIA TM , BD Biosciences Pharmingen, San Diego, USA).
Immunization of mice with mouse BM-DC loaded with soluble or PLGA-MS-encapsulated antigens
Murine CD11c + BM-DC prepared from C57BL/6 mice were loaded with soluble or PLGA-MS-encapsulated peptide I8V (␤-gal 497-504 ) or ␤-gal protein and activated with LPS, as indicated in Fig. 5 . After washing to remove free antigens, 3 × 10 5 Ag-loaded BM-DC were injected into B6 mice intravenously at the tail vein (three mice per group). 
Determination of I8V-specific CTL by I8V/H-2K b tetramer staining
Three to five drops of blood were collected from immunized mice by tail bleeding at the indicated time points. Blood was collected in FACS-EDTA buffer (PBS containing 2% FCS, 0.5 M EDTA and 0.03% NaN 3 ), and stained with PE-labeled I8V/H-2K b tetramer for 10 min at 37 • C, and subsequently with FITC-labeled anti-CD8 mAb for 20 min at 4 • C. Erythrocytes were then lysed with BD FACS TM Lysing Solution (BD Biosciences, Erembodegem, Belgium), cells were washed once and resuspended in 500 l FACS buffer for flow cytometric analysis with a FACScan ® flow cytometer (Becton Dickinson). 51 Cr release assay was used to determine the function of I8V/H-2K b tetramer positive CTL. EL-4 target cells were either pulsed with 1 g/ml of I8V peptide or left unpulsed and were labeled with 51 Cr for 1 h at 37 • C. After washing, labeled target cells (2000 cells in 100 l) were added to various numbers of effector cells (splenocytes from immunized mice after one cycle of re stimulation) in Ubottom 96-well microplates. Chromium release was measured in the supernatant (100 l) after 4 h of incubation at 37 • C.
Cytolytic assay
Results
Delivery of tetanus toxoid antigens to human MoDC via PLGA-MS prolongs MHC class II-restricted antigen presentation
To assess the efficiency of MHC classes I and II-restricted antigen presentation by human MoDC, we first determined the cell surface expression of MHC molecules and DC maturation markers before and after uptake of PLGA-MS. In agreement with previous investigations [20] , the surface expression of CD80, CD83, CD86, HLA-DR, HLA-A2 and CCR7 was not altered after uptake of PLGA-MS by immature MoDC. Moreover, PLGA-MS uptake did not induce MoDC maturation, but MoDC loaded with PLGA-MS could be matured with a cocktail of proinflammatory cytokines (TNF-␣, IL-1␤, IL-6, PGE2), as indicated by the upregulation of aforementioned markers (Fig. 1) .
To assess class II-restricted presentation, immature MoDC were loaded with different concentrations of the HLA-DR5-restricted tt30 peptide from tetanus toxoid protein (TT) either in soluble or PLGA-MS-encapsulated form. Antigenpulsed MoDC were then left immature or were matured with the proinflammatory cytokines (Fig. 2) . MoDC were then incubated with the HLA-DR5/tt30 specific CD4 + Thelper cell line SK30 and T cell proliferation was monitored ( Fig. 2A-D) . For immature MoDC, loading with soluble tt30 peptide seemed to be more efficient than with PLGA-MSencapsulated tt30 (MS-tt30, Fig. 2A ) but this difference was not observed with matured MoDC where both methods were equally efficient (Fig. 2C) . When TT protein was used as antigen, 10-fold lower amounts of TT were required for tt30 presentation when it was delivered via PLGA-MS (MS-TT, Fig. 2D ). To substantiate this result, we also used the oligoclonal TT specific CD4 + cell line KR.TT to monitor TT presentation (Fig. 2E-H) . Proliferation of KR.TT cells could be detected when MoDC were loaded with 0.1 ng/ml PLGA-MS-encapsulated TT, while at least 10-fold larger quantities (1.0-10 ng) were needed to achieve an equivalent stimulation with soluble TT (Fig. 2E and F) .
Next, we performed a kinetic analysis of TT presentation. Immature MoDC were loaded with either soluble or PLGA-MS-encapsulated TT at a saturating concentration of 1.0 g/ml (Fig. 2G) or at a limiting concentration of 0.01 g/ml (Fig. 2H ). MoDC were then matured with proinflammatory cytokines, and TT-presentation was recorded with KR.TT cells after several days. Antigen delivery of TT via PLGA-MS was clearly superior to pulsing with soluble protein, which became apparent on day 10 after antigen loading with 0.01 g/ml TT when the presentation of PLGA-MSencapsulated TT persisted, whereas presentation of soluble TT had waned.
Prolongation and enhancement of MHC class I-restricted cross-presentation by encapsulation of influenza virus matrix protein and peptide
We investigated cross-presentation of PLGA-MSencapsulated proteins and peptides using the influenza virus matrix protein (FluM) and the HLA-A * 0201 restricted M1 epitope (FluM 58-66 ) as model antigens. First, external loading of mature MoDC with the M1 epitope was compared to loading immature MoDC with PLGA-MS-encapsulated M1 (MS-Flu peptide) followed by DC maturation in vitro. M1-presentation was monitored by IFN-␥ production of an M1/HLA-A * 0201-specific CTL line during several days after antigen pulsing (Fig. 3A) . Interestingly, MS-Flu peptide presentation persisted up to day 7 while presentation ceased on day 4 after external peptide loading. The presentation of externally loaded peptide declined continuously whereas presentation of PLGA-MS-encapsulated FluM peptide was maximal one day after delivery which coincides with the so called burst release of encapsulated material from PLGA-MS known to occur within the first day of incubation. To ascertain that M1 presentation from PLGA-MS was not due to peptide release and external binding to class I molecules during coincubation, we incubated MoDC with the supernatant of MSFlu peptide which was obtained after 24 h of release in T cell medium with the same concentration as used for MS-loading. Since only negligible antigen presentation was detected (Fig. 3A, SN MS-Flu peptide) , it appears that Ml-loading of HLA-A * 0201 molecules of MoDC occurred within the cells. Fig. 4 . The uptake of PLGA-MS by murine BM-DC. CD11c + murine BM-DC were loaded with PLGA-MS that contained the fluorescent dye Rhodamine B (MS-RB) and were then activated overnight with LPS followed by the analysis of MS-RB uptake by flow cytometry (upper panels). Numbers within the dot plot gates represent percentage of BM-DC that were positive for RB fluorescence. The phenotype of fluorescent CD11c + BM-DC was determined by surface staining with mAbs specific for CD54, CD86, and H2-I-A b followed by flow cytometric analysis (filled black lines). Open black lines represent BM-DC without Ab staining. BM-DC without MS loading were used as negative control. Data represent one out of three independent experiments which all gave similar results.
To examine how a model protein can be cross-presented from PLGA-MS, a recombinant GST-influenza matrix fusion protein (FluM) was encapsulated into PLGA-MS (MS-FluM) and immature MoDC were incubated with MSFluM at different concentrations and subsequently matured. For comparison, untreated MoDC were incubated with the equivalent amount of soluble FluM and presentation of the M1 epitope was monitored (Fig. 3B) . Remarkably, 50 g/ml of soluble FluM was not sufficient to achieve a level of CTL stimulation obtained with only 1 g/ml of FluM after uptake via PLGA-MS. A kinetic experiment was then performed to compare stimulation of M1-specific CTL at different time points after MoDC had been loaded with either soluble FluM or MS-FluM. As shown in Fig. 3C , presentation of soluble FluM protein was very low and vanished completely after one or two days, whereas presentation of MS-FluM lasted for at least 3 days.
DC-based vaccination of mice elicits strong CTL responses when a protein or peptide is delivered to DC via PLGA-MS
To investigate the antigen specific CTL response elicited by PLGA-MS treated DC in vivo we switched to the mouse model. First, we tested whether murine bone marrow-derived DC (BM-DC) phagocytose PLGA-MS in vitro as efficiently as human MoDC. BM-DC were incubated overnight with PLGA-MS that contained the fluorescent dye Rhodamine B (MS-RB), and the portion of fluorescent cells was determined by flow cytometry (Fig. 4, top panels) . About 60% of the BM-DC were fluorescent after overnight incubation which is even a bit higher than what we have recently observed in similar experiments for human MoDC where about 45% of the cells had engulfed PLGA-MS [20] . To monitor the effect of PLGA-MS uptake on the cell surface phenotype of BM-DC I8V) . Alternatively, BM-DC were loaded with 1 g/ml of PLGA-MS-encapsulated (MS-␤Gal) or soluble (sol.␤-Gal) ␤-gal protein for 4 h at 37 • C followed by maturation with LPS for 24 h. BM-DC loaded with empty PLGA-MS (MS-E) or without Ag loading (w/o Ag) were used as controls. After washing, 3 × 10 5 BM-DC were injected intravenously into C57BL/6 mice (three mice per group). After 6, 10, and 16 days of immunization, PBL from each mouse were collected to detect ex vivo I8V-specific CD8 + T cells in peripheral blood by I8V-tetramer staining. The flow cytometric analysis of one representative mouse in each group on day 6 are shown in (A). The numbers in the dot plots represent the mean percentage of I8V-tetramer positive CD8 + T cells of each group (three mice) ± S.E.M. The kinetic analysis of the CTL responses is shown in (B). On day 16 after immunization, splenocytes from each mouse were restimulated with I8V peptide for 6 days in vitro and then analyzed by I8V-tetramer staining (C) and 51 Cr release assay using EL-4 cells pulsed with (closed symbols) or without I8V peptide (open symbols) as targets (D). Each symbol represents one mouse; results are averaged from two independent experiments. we stained BM-DC for CD54, CD86 and H-2IA b before and after uptake of PLGA-MS. However, no significant change was revealed by flow cytometric analysis (Fig. 4) .
To monitor antigen-specific CTL generation in mice, we used adoptive transfer of bone marrow-derived DC in mice. For this purpose, we prepared PLGA-MS that contained the model antigen ␤-galactosidase (MS-␤gal) or the H-2K brestricted I8V epitope of ␤-gal (MS-I8V, residues 497-504). Then, CD11c + BM-DC were loaded with soluble I8V peptide, MS-I8V, soluble ␤-gal, MS-␤gal, or empty PLGA-MS (MS-E) and subsequently injected i.v. into C57/BL6 mice. The expansion of I8V-specific CTL in vivo was assessed on day 6 after inoculation by staining of PBL with I8V/H-2K b tetramers and anti-CD8 Ab. Flow cytometric analysis indicated that BM-DC loaded with MS-I8V were slightly more potent than BM-DC pulsed with the soluble I8V peptide (Fig. 5A) . Interestingly, BM-DC loaded with MS-␤gal were much more effective than BM-DC charged with the soluble ␤-gal protein. A kinetic analysis of the CTL response over 16 days post inoculation revealed that the I8V-specific response was longer lasting when the peptide was delivered to BM-DC via PLGA-MS (Fig. 5B) . On days 10 and 16 after inoculation, respectively, three and two times more I8V specific CTLs were detected when antigen delivery occurred with PLGA-MS. In addition to CTL specificity we also assessed cytolytic function. Splenocytes that were recovered on day 16 after vaccination were restimulated in vitro for 6 days with BM-DC loaded with I8V peptide. Staining with I8V/H-2K b tetramers revealed that the in vitro expansion did not distort the relative frequencies observed ex vivo (Fig. 5C ). The cytolytic assays that were performed subsequently indicated that cytolytic activity correlated well with the frequency of I8V specific CTL, thus indicating that the generated CTL were functionally intact (Fig. 5D ).
Discussion
The delivery of antigens to DC in a manner that allows the generation of strong and enduring antigen-specific CTL and T helper cell responses has been a persisting challenge for DC-based immunotherapy. While pulsing with peptides is convenient, it has the disadvantage that peptides remain bound to cell surface expressed class I molecules for only a few hours. Moreover, peptide-based immunotherapy will remain confined to a subgroup of patients that express the appropriate restriction elements. Another problem is the lack of specific T cell help because it is still quite difficult to identify class II epitopes; thus, the probability that appropriate classes I and II epitopes are available for a certain patient is very low. Therefore, most DC-based trials resorted to loading DC with a tumor-specific CTL epitope combined with a tumor-unrelated protein as a source of Th epitopes. This approach, however, is not optimal since specific T cell help is needed for the optimal induction of CTL [24] .
A much better solution would be to load MoDC with protein antigens which have a high probability of containing both MHC classes I and II epitopes for a patient's ensemble of restriction elements. Unfortunately, it has been shown for murine and human DC that the cross-presentation of soluble proteins is extremely inefficient and we have confirmed this for the influenza virus matrix protein and human MoDC in vitro (Fig. 3) and for ␤-galactosidase and murine BM-DC in vivo (Fig. 5) . Alternative methods for introducing proteins into the classes I and II pathways via transfection of mRNA or infection with viral vectors have been pursued, but problems with the preservation of DC integrity and function, with the transfection efficiency, the generation of anti-viral antibodies, and safety concerns have not yet been resolved.
In this study, we have investigated the loading of human MoDC with peptides and proteins via encapsulation into PLGA microparticles. This approach circumvents many of the aforementioned pitfalls. Safety issues should not arise with this approach as no nucleic acids or infectious processes are involved and since the PLGA polymer is clinically approved and biodegrades into acids that are rapidly metabolized. Previously, we have shown that crucial functions of MoDC were not negatively affected by the uptake of PLGA-MS [20] . Here, we have investigated the question of specific classes I and II-restricted antigen presentation after loading of MoDC with PLGA-MS-encapsulated proteins and peptides. In agreement with previous studies with murine and human macrophages as well as murine dendritic cells, we also find for human MoDC that PLGA-MS-encapsulated proteins are very efficiently presented on class I (Fig. 3 ) and class II (Fig. 2) molecules. For both model proteins, tetanus toxoid and GST-Flu matrix, which were used for the investigation of class II and class I presentation, respectively, we compared the efficiency of presentation achieved with the soluble and PLGA-MS-encapsulated form. For class II presentation the enhancement of presentation afforded by delivery via PLGA-MS was only apparent when limiting amounts of tetanus toxoid (TT) were used and when MoDC were matured after antigen delivery. Nevertheless, a roughly 10-fold increase in sensitivity was observed with two different detection systems (Fig. 2) . A more striking advantage of PLGA-MS-mediated antigen delivery, however, is the efficient class I-restricted cross-presentation by MoDC. Crosspresentation of PLGA-MS-encapsulated GST-Flu matrix was at least 50-fold more efficient than that of soluble GST-Flu matrix protein (Fig. 3B) . This impressive enhancement in cross-presentation is probably not a unique property of the PLGA polymer, but rather a general property of microparticles with a diameter of 0.1-5 m as similar findings have been made in murine dendritic cells and macrophages with iron oxide beads [25] , latex beads [5] , or polysaccharides [26] of a similar size.
In addition to facilitating and enhancing classes I and II-restricted presentation, loading MoDC with PLGA-MS affords a striking prolongation of antigen presentation. This property was apparent for class II-restricted presentation of tetanus toxoid when it was applied to MoDC at a low concentration (Fig. 2H ), but it was even more prominent for class I-restricted cross-presentation of the M1 epitope of influenza virus matrix protein (Fig. 3A) . Compared to loading with soluble M1 peptide, the loading with PLGA-MS achieved a duplication of the time period of M1 presentation (Fig. 3A) . The efficient M1 presentation is interesting in the light of reports that cell-associated peptides cannot be crosspresented [27] [28] [29] . It appears that the encapsulation into PLGA-MS protects peptides from degradation which may be due to a release of PLGA-MS fiom the endo/lysosome into the cytosol, as was recently demonstrated for PLGA nanoparticles [30] . Presentation of the M1 epitope was detected up to three days after charging MoDC with PLGA-MSencapsultated GST-FluM protein. This is only half of the time period of M1 presentation which we achieved with PLGA-MS encapsulated M1 peptide. However, keeping in mind that 500-3000 proteins may need to be degraded in order to generate one CTL epitope [31] , the lower level and duration of presentation is not unexpected.
To investigate if this improvement of antigen presentation translates into better CTL responses in vivo, we examined the generation of CTL specific for the I8V peptide of ␤-galactosidase in the mouse model. Interestingly, the efficiency of CTL generation in vivo paralleled the characteristics of antigen presentation by MoDC in vitro (Fig. 5) in that PLGA-MS-mediated peptide delivery to BM-DC led to a significant increase in the number of I8V-specific CTL on day 6 post vaccination, which was augmented to a three-fold increase on day 10 after vaccination (Fig. 5B ). In accordance with our in vitro results with human MoDC, no significant CTL response could be obtained when BM-DC were loaded with soluble ␤-galactosidase protein, but almost 5% of CD8 + T cells were specific for the I8V peptide on day 6 after vaccination with BM-DC when they were loaded with PLGA-MS encapsulated P-galactosidase. This protocol of DC-based vaccination afforded not only a strong increase in CTL numbers, but the CTL were also functional as determined by cytolytic tests (Fig. 5D) .
Taken together, we show in this study that antigen delivery to human MoDC by PLGA-MS has important advantages for DC-based vaccination in vitro and in vivo. Since the protocols for MoDC generation used in this study are suitable for clinical application and since PLGA is a pharmaceutically accepted material, our investigations set the stage for testing this technique of antigen delivery in clinical trials of DCbased immunotherapy against tumors and infectious diseases.
